学术探索
学术期刊
学术作者
新闻热点
数据分析
智能评审

Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial

被引：16
作者：
Crawford, E. David
Andriole, Gerald L.
Marberger, Michael
Rittmaster, Roger S.
机构：
[1] Univ Colorado, Hlth Sci Ctr, Dept Urol Oncol, Denver, CO USA
[2] Washington Univ, Sch Med, Div Urol Surg, Siteman Canc Ctr, St Louis, MO 63110 USA
[3] Med Univ Vienna, Dept Urol, Vienna, Austria
[4] GlaxoSmithKline, Biomed Data Sci, Res Triangle Pk, NC USA
来源：
UROLOGY | 2010年 / 75卷 / 03期
关键词：
5-ALPHA-REDUCTASE INHIBITOR DUTASTERIDE; HIGH-GRADE; COST-EFFECTIVENESS; VITAMIN-E; FINASTERIDE; MEN; BIOPSY; CHEMOPREVENTION; IMPACT; LIFE;
D O I：
10.1016/j.urology.2009.05.099
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
100201 [内科学]; 100221 [泌尿外科学];
摘要：
The landmark Prostate Cancer Prevention Trial (PCPT) generated interest in the potential health benefits and cost of reducing prostate cancer risk-specifically, the potential role of 5 alpha-reductase inhibitors. However, the PCPT raised several unanswered questions, including the cause and significance of the increased incidence of high-grade tumors associated with finasteride. In the present study, we review the PCPT findings and unanswered questions, next steps in this field, and ongoing prostate cancer prevention trials addressing these unanswered questions. Particular emphasis is placed on the design of the second large-scale trial of a 5 alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. UROLOGY 75: 502-510, 2010. (C) 2010 Elsevier Inc.
引用
收藏
页码：502 / 509
页数：8
相关论文
共 51 条
[1]
Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial [J].
Andriole, G ;
Bostwick, D ;
Brawley, O ;
Gomella, L ;
Tindall, D ;
Breed, S ;
Somerville, M ;
Rittmaster, R .
JOURNAL OF UROLOGY, 2004, 172 (04) :1314-1317
[2]
ANDRIOLE G, 2009, AM UR ASS ANN M CHIC
[3]
Andriole GL, 2004, UROLOGY, V64, P537, DOI 10.1016/j.urology.2004.04.084
[4]
Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer [J].
Andriole, GL ;
Humphrey, P ;
Ray, P ;
Gleave, ME ;
Trachtenberg, J ;
Thomas, LN ;
Lazier, CB ;
Rittmaster, RS .
JOURNAL OF UROLOGY, 2004, 172 (03) :915-919
[5]
Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment [J].
Bhatnagar, V. ;
Stewart, S. T. ;
Huynh, V. ;
Jorgensen, G. ;
Kaplan, R. M. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (02) :136-146
[6]
Prostate volume and adverse prostate cancer features: Fact not artifact [J].
Briyanti, Alberto ;
Chun, Felix K. -H. ;
Suardi, Nazareno ;
Gallina, Andrea ;
Walz, Jochen ;
Graefen, Markus ;
Shariat, Shahrokh ;
Ebersdobler, Andreas ;
Rigatti, Patrizio ;
Perrotte, Paul ;
Saad, Fred ;
Montorsi, Francesco ;
Huland, Hartwig ;
Karakiewicz, Pierre I. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (18) :2669-2677
[7]
Looking back at PCPT: Looking forward to new paradigms in prostate cancer screening and prevention [J].
Canby-Hagino, Edith ;
Hernandez, Javier ;
Brand, Timothy C. ;
Thompson, Ian .
EUROPEAN UROLOGY, 2007, 51 (01) :27-33
[8]
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor [J].
Clark, RV ;
Hermann, DJ ;
Cunningham, GR ;
Wilson, TH ;
Morrill, BB ;
Hobbs, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2179-2184
[9]
Detection bias due to the effect of Finasteride on prostate volume: A modeling approach for analysis of the prostate cancer prevention trial [J].
Cohen, Yael C. ;
Liu, Kenneth S. ;
Heyden, Norman L. ;
Carides, Alexandra D. ;
Anderson, Keaven M. ;
Daifotis, Anastasia G. ;
Gann, Peter H. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (18) :1366-1374
[10]
Prostate cancer prevention and finasteride [J].
D'Amico, Anthony V. ;
Barry, Michael J. .
JOURNAL OF UROLOGY, 2006, 176 (05) :2010-2012
123456